Trial · NCT01296815
Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
NCT01296815, Phase 2, Completed, Centro de Investigación en. Enfermedades Infecciosas, Mexico; results first posted 2015-07-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity. Trials, record NCT01296815. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01296815
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
- NCT number
- NCT01296815
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 14 participants, actual
- Lead sponsor
- Centro de Investigación en. Enfermedades Infecciosas, Mexico
- Conditions
- Kaposi´s Sarcoma
- Interventions
- Bevacizumab
- First posted
- 2011-02-16
- Last updated
- 2015-07-27
- Results first posted
- 2015-07-27
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Complete Response | 12 months | Complete response will be assessed according to RECIST criteria |
| Secondary | Safety | 12 months | Adverse events will be assessed according to the Council for International Organizations of Medical Sciences (CIOMS) I Working Group the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Complete Response | 12 months | participants | NUMBER | |
| SECONDARY | Safety | 12 months |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Complete Response | HAART | 1 | participants | ||
| Number of Participants With Complete Response | HAART+ Bevacizumab Injection | 3 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | HAART | 7 | |
| Overall Study | STARTED | HAART+ Bevacizumab Injection | 7 | |
| Overall Study | COMPLETED | HAART | 7 | |
| Overall Study | COMPLETED | HAART+ Bevacizumab Injection | 7 | |
| Overall Study | NOT COMPLETED | HAART | 0 | |
| Overall Study | NOT COMPLETED | HAART+ Bevacizumab Injection | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Fever | Respiratory, thoracic and mediastinal disorders | HAART | 0 | 7 | 0 |
| serious | Fever | Respiratory, thoracic and mediastinal disorders | HAART+ Bevacizumab Injection | 1 | 7 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | HAART | ||
| Total, all-cause mortality | HAART+ Bevacizumab Injection | ||
| Total, other adverse events | HAART | 0 | 7 |
| Total, other adverse events | HAART+ Bevacizumab Injection | 0 | 7 |
| Total, serious adverse events | HAART | 0 | 7 |
| Total, serious adverse events | HAART+ Bevacizumab Injection | 1 | 7 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 25345840 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| HAART vs HAART+ Bevacizumab Injection: Number of Participants With Complete Response | Trial comparisons |
| HAART vs HAART+ Bevacizumab Injection: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01296815
GET https://conductscience.org/api/trials/v1/NCT01296815/registered